Outlines 2021 product pipeline milestones for COVID-19, influenza A and norovirus antiviral programsEnds 2020 with cash exceeding $33 million and...
Results
CHARLOTTESVILLE, Va., March 17, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical...
- UPLIFT, a single-arm registration strategy evaluating upifitamab rilsodotin (UpRi) in platinum-resistant ovarian cancer, on track to begin in Q1...
VXA-CoV2-1 oral COVID-19 vaccine candidate targeting both the S and N proteins is planned to advance to Phase 2 testing...
- Initiated the Phase 2b SOOTHE clinical trial in refractory chronic cough; topline results expected Q4 2021 with an interim...
– 2020 Highlights Include: Enrollment Completion of Pivotal PHYOX™2 Trial of Nedosiran for Primary Hyperoxaluria; Positive RG6346 Phase 1 Data...
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a...
MAUMEE, Ohio, Feb. 18, 2021 /PRNewswire/ --Dana Incorporated logo. (PRNewsFoto/Dana Incorporated)Full-year ResultsSales of $7.1 billion, a decrease of $1.5 billion...
InvestorPlace10 Dividend Stocks Increasing Their PayoutsThere are two types of dividend stocks: those that increase their annual dividend payments year...
Top-Line Data from Pivotal SORAYA Trial for Mirvetuximab Soravtansine in Ovarian Cancer Expected in Q3 2021; BLA to be Submitted...